

Date: 20/05/2017

To

Deputy Manager Dept. of Corporate Services, Bombay Stock Exchange Limited P J Towers, Dalal Street, Fort, MUMBAI - 400001

Dear Sir/Madam,

Sub: Revised Audited financial results for the quarter and year ended on 31st March, 2017

Reg. 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015; Script Code# 511509

With reference to subject cited above we are herewith enclosing Revised Audited Financial results for the quarter and year ended on 31st March, 2017 as there is some typographical error.

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Cimited

M Kalyan Ram

Whole Time Director

DIN: 02012580

Address of Preclinical Research Facility: Sy. # 349/A, Pregnapur - 502 311, Gajwel Mandal, Medak District. T.S. INDIA.

Phone: +91-40-27890662-5, Fax: +91-40-27890669 website: www.vivobio.com

Date: 19/05/2017

To

Deputy Manager Dept. of Corporate Services, Bombay Stock Exchange Limited P J Towers, Dalal Street, Fort, MUMBAI - 400001

Dear Sir/Madam,

Sub: Audited financial results for the quarter and year ended on 31st March, 2017

Reg. 33 of SEBI (Listing obligations and Disclosure Requirements) Ref: Regulations, 2015; Script Code# 511509

With reference to subject cited above the board of Directors of the company in their meeting held on 19th May, 2017 has approved Audited financial results for the quarter and year ended on 31st March, 2017. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Audited Financial results for the quarter and year ended on 31st March, 2017 along with Audit Report issued by the Statutory Auditors of the company.

This is for your record and reference.

Thanking you,

Yours faithfully

For Vivo Big Tech Limited

M Kalyan Ram

Whole Time Director

DIN: 02012580

Phone: +91-40-27890662-5, Fax: +91-40-27890669 website: www.vivobio.com

## Vivo Bio Tech Ltd. Your Drug Discovery Partner

WHOLE TIME DIRECTOR Op. DIN :02012580

	-		t March, 2017	r ended on 31s	Quarter and Yea	Statement of Audited Financial Results for the		
ed	ar En	Yea	QUARTER ENDED			June		
3.2016	31.	31.03.2017	1 03 2017 31.12.2016 31.03.2016 31.03.2		31.03.2017	PARTICULARS	5.No.	No.
ted	Au	Audited	Audited	Unaudited	31.03.201	1	.140.	
				Onedante	Audited			
2,851.90	6	3212.06	735.09	841.91	854.98	Income from Operations	1	
6.43	4	200.74	0.00	5.87	0.00	a) Net Sales/ Income from Operations	- A	
2858.33	0		735.09	847.78	854.98	b) Other Operating Income		
3, 3, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6,				047.70	634,36	Total Income from operations		
60.56	2	-47.72	50.56	(142.85)	54.32	Expenses	2	
819.29	8	-	42.73	296.83	159.33	a) Increase/(decrease) in stock in trade and WIP		
0.0	0		0.00		0.00	b) Consumption of Raw materials		
434.26	1		127.35	133.06	147.62	c) Purchase of traded goods		
335.40	-		91.68	99.72	109.76	d) Employees Cost		
			52.00	00.72	109.76	e) Depreciation		
1,173.46	94	1285.94	448.65	307.05	220.26	f)Other Expenditure		
2822.9	_			1	339.36	1)Administrative Expenditure		
			700.51	093.01	810.39	Total		
35.3	85	372.85	-25.88	153.97		Profit/loss from Operations before other income, finance cost		
89.2	-	-	-		44.60	and exceptions items(1-2)	3	
		33.2	31.50	0.00	3.61	Other income	4	
124.6	41	9 412.4	5.69	453.03	7	Profit/(loss) from Ordinary activities before finance costs and		
46.5	_	-	-		48.21	exceptional items(3+4)	5	
	-	110.0	15.54	37.00	53,47	Figures costs	6	
78.0	53	5 283.5	-9.85	05.00		Profit/(loss) from Ordinary activities after finance costs but before		
0.0	-				(5.26	exceptional items(5-6)	7	
78.0	_			0.00		Exceptional items	8	
(12.9	_			The second secon	(5.26	Profit/Loss from Ordinary Activities before tax(7-8)	9	
91.	_				(27.4)	Tax Expense	10	
0.	.00				22.14	Net Profit/Loss from Ordinary Activities after Tax(9-10)	11	
91.	-			The second secon	0.0	Extraordinary Items (Net of Tax expense of RsLakh)	12	
935				The state of the s	22.1	Net Profit/Loss for the Period(11-12)	13	
de	7.40	05 9301	5 935.0	935.0	935.0	Paid Up Share Capital(Face Value of Rs.10/-each)	14	
73				all core	100	Reserves Excluding Revaluation Reserves as per Balance sheet of	14	
73.	.65	00 323.6	0.0	0.0	0.0	previous accouting year		
0		-		2		Earning Per Share(EPS)(Before Extraordinary items)	15	
0	.68	-			0.2		16.1	
U	2.68	32 2.0	8 0.3	4 0.7	0.2	a)Basic		
6 0	-					b)Diluted Earning Per Share(EPS)(After Extraordinary items)		
CH	68	-	the state of the s		0.2		16.ii	
TECH LIMIT	2,68	32 //22	78 0.3	4 0.7	0.2	a) Basic b) Diluted		

Registered Office: #608, 6th Floor, Lingapur, Himayath Nagar, Hyderabad - 500 029. T.S. INDIA.

Address of Preclinical Research Facility: Sy. # 349/A, Pregnapur - 502 311, Gajwel Mandal, Medak District. T.S. INDIA.

Phone: +91-40-27890662-5, Fax: +91-40-27890669 website: www.vivobio.com

## Vivo Bio Tech Ltd. **Your Drug Discovery Partner**

	- f Access and Liabilities		In Rupees			
Particulars		As A1 31/03/2017		Auditon		
	QUITY AND LIABILITIES					
E	hareholders' funds	02 505 200	93,505,200			
		93,505,200	7,325,870			
a	) Share Capital	32,364,662	100,831,070			
b	Reserves and Surplus sub-total -Shareholders' Funds	125,869,862	100,032,010			
S	ub-total -Shareholders Pullos					
-	Non-Current Liabilities	209,323,034	141,061,169			
-41	a)Long Term borrowings	7,817,914	8,405,859			
-	b) Defffered tax liabilites	7,017,514				
-	c)Other Long term liabilities	2615494	2,030,215			
-	d) Long term provisions	219,756,442	154 407 242			
-	Sub-total -Non-Current Liabilities	219,750,442				
	Sub-total -Non-current					
3	Current Liabilities	61,227,141	28,050,004			
	a) Short-term Borrowings	54,007,721	87,463,132			
_	b) Trade Payables	39,197,49	77,213,127			
	c)Other Curren Liabilities	11,295,28	** CCO F70			
_	d) Short Term provisions	165,727,63				
_	Sub-total -Current Liabilities	103,727,00				
	Sub-total sub-	511,353,93	9 456,715,154			
	TOTAL-EQUITY AND LIABILITIES	311,333,33				
В	ASSETS  1 Non-Current Assets		40 169,423,714			
1	a)Fixed Assets	228,419,5	54.070.55A			
	i)Tangible Assets	55,317,3	440 407			
	ii) Intangible Assets	29,603,2	222 227			
	(iii) Capital Work-in-progress	300,0				
	b) Non-Current Investments	261,1	360,337			
	c) Other non-current assets	313,901,1	234,583,19			
	Sub-total Non-Current Assets					
			882 40,814,02			
_	2 Current Assets	45,585,	25.400.75			
L	a) Inventories	76,658,	140 511 00			
	b) Trade Receivables	11,845,	1// 110,511,05			
	c)Cash and cash equivalents		598 8,620,53			
	d) short term loans and advances	44,618 18,744	2055			
-	e) Other current assets	197,452	,367			
-	Sub-Total Current Assets	197,452	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
-	Sub-10tal current rissers	511,353	3,939 456,715,1			
-	TOTAL ASSETS	511,353	10 BIOTE			
1	Place: Hyderabad Date:19th May 2017	M Who	For Vivo Bio Tech Limited  M Kalyan Ram Whole Time Director DIN: 02012580			

Registered Office: #608, 6th Floor, Lingapur, Himayath Nagar, Hyderabad - 500 029. T.S. INDIA.

Address of Preclinical Research Facility: Sy. # 349/A, Pregnapur - 502 311, Gajwel Mandal, Medak District. T.S. INDIA. Phone: +91-40-27890662-5, Fax: +91-40-27890669 website: www.vivobio.com

## Vivo Bio Tech Ltd. Your Drug Discovery Partner

## Notes:

- The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 19th May, 2017.
- The entire operations of the company relate to single segment viz., Bio Technology. Hence Segmental Reporting is not required to be made under AS-17.
- The figures for the current quarter are the balancing figures between the audited figures in respect of full financial year and the published year to date figures up to the third quarter of the respective financial years.
- An Extract of the detailed format of audited financial results filed with stock exchange under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 will be published in Newspaper.

5. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Date: 19th May, 2017

Place: Hyderabad

For Vivo Bio Tech Limited

M Kalyan Ram Whole Time Director

DIN: 02012580

Registered Office: #608, 6th Floor, Lingapur, Himayath Nagar, Hyderabad - 500 029. T.S. INDIA.

Address of Preclinical Research Facility: Sy. # 349/A, Pregnapur - 502 311, Gajwel Mandal, Medak District. T.S. INDIA.

Phone: +91-40-27890662-5, Fax: +91-40-27890669 website: www.vivobio.com